Compare · OGN vs TXMD
OGN vs TXMD
Side-by-side comparison of Organon & Co. (OGN) and TherapeuticsMD Inc. (TXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OGN and TXMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- OGN is the larger of the two at $3.65B, about 170.3x TXMD ($21.4M).
- OGN has hit the wire 10 times in the past 4 weeks while TXMD has been quiet.
- OGN has more recent analyst coverage (19 ratings vs 2 for TXMD).
- Company
- Organon & Co.
- TherapeuticsMD Inc.
- Price
- -
- -
- Market cap
- $3.65B
- $21.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 19
- 2
Organon & Co.
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
TherapeuticsMD Inc.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Latest OGN
- Head of Mfg & Supply Drinane Juliana Papa converted options into 3,626 shares and covered exercise/tax liability with 1,242 shares, increasing direct ownership by 13% to 20,859 units (SEC Form 4)
- Head of R&D & CMO Arjona Ferreira Juan Camilo converted options into 6,447 shares and covered exercise/tax liability with 2,314 shares, increasing direct ownership by 11% to 41,565 units (SEC Form 4)
- SVP and Corporate Controller Holzbaur Lynette converted options into 5,456 shares and covered exercise/tax liability with 1,555 shares (SEC Form 4)
- New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
- Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
- Organon Announces Quarterly Dividend
- Organon & Co. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Organon & Co.
- Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
- Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Latest TXMD
- SEC Form 10-Q filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TherapeuticsMD Announces Second Quarter 2026 Financial Results
- SEC Form 10-Q filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TherapeuticsMD Announces First Quarter 2026 Financial Results
- Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.
- SEC Form NT 10-K filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by TherapeuticsMD Inc.